To report on the dosimetric benefits and late toxicity outcomes after injection of hydrogel spacer (HS) between the prostate and rectum for patients treated with prostate radiotherapy (RT).
Objective
To report on the dosimetric benefits and late toxicity outcomes after injection of hydrogel spacer (HS) between the prostate and rectum for patients treated with prostate radiotherapy (RT).
Patients and Methods
In all, 76 patients with a clinical stage of T1-T3a prostate cancer underwent general anaesthesia for fiducial marker insertion plus injection of the HS into the perirectal space before intensity-modulated RT (IMRT) or volumetricmodulated arc RT (VMAT). HS safety, dosimetric benefits, and the immediate-to long-term effects of gastrointestinal (GI) toxicity were assessed.
Results
There were no postoperative complications reported. The mean (range) prostate size was 66.0 (25.0-187.0) mm. Rectal dose volume parameters were observed and the volume of rectum receiving 70 Gy (rV 70 ), 75 Gy (rV 75 ) and 78 Gy (rV 78 ) was 7.8%, 3.6% and 0.4%, respectively. In all, 21% of patients (16/76) developed acute Grade 1 GI toxicities, but all were resolved completely by 3 months after treatment; whilst, 3% of patients (2/76) developed late Grade 1 GI toxicities. No patients had acute or late Grade ≥2 GI toxicities.
Introduction
It is estimated that there will be~16 665 prostate cancer diagnoses in 2017, resulting in the deaths of >3 452 Australian men [1] . Radiotherapy (RT) remains a highly effective treatment for patients with localised disease. Whilst advanced RT planning techniques, such as intensitymodulated RT (IMRT) and volumetric-modulated arc RT (VMAT), have enabled dose escalation to the prostate and reduced toxicity, it is often associated with increased genitourinary (GU) and gastrointestinal (GI) toxicities, and rectal toxicity in particular. It is well documented that late rectal toxicity is correlated to the volume of the anterior rectal wall receiving a higher dose, especially the volume of rectum receiving 70 Gy (rV 70 ) [2] . Reducing this volume during treatment will minimise rectal toxicity and one of the most simple and effective ways is to increase the distance between the rectum and the prostate.
Although recent advances in RT delivery, including imageguided RT (IGRT), IMRT and VMAT have reduced toxicity rates, it has proven a challenge to spare the anterior rectal wall. Several different methods to reduce the rectal toxicity rate, such as collagen, hyaluronic acid and blood patch, have been explored with minimal success [3] [4] [5] [6] . Hydrogel spacer (HS) implanted between the prostate and rectum in recent years has gained noticeable interest in increasing the perirectal spacing and reducing RT-related rectal toxicity [7] , either in external beam RT alone, low-or high-dose rate brachytherapy, or a combination of both external beam RT and brachytherapy [8, 9] .
The safety and efficacy of HS in a prostate RT setting have been reported by several studies. More so, two systematic reviews demonstrated minimal acute and early post-RT toxicities [10, 11] . However, as with any new technique more information is needed to verify the efficacy of HS, particularly from different regions and centres [12] [13] [14] . Therefore, the present study aimed to report on our initial experience of using a HS implant in men with prostate cancer treated with prostate RT.
Patients and Methods

Study Design
This review of a prospectively collected dataset examined the clinical safety and efficacy of the use of HS between the prostate and rectum (SpaceOAR â ; Augmenix Inc., Waltham, MA, USA) for men undergoing a course of IMRT or VMAT. Our institution's Human Research and Ethics Committee approved our treatment protocol before commencement. All participants provided written medical informed consent before undergoing any therapeutic procedure.
Participants
In all, 76 patients with confirmed prostate cancer from Radiation Oncology Victoria, Melbourne, Australia, were enrolled into the study from December 2013 to December 2015. Eligible patients were consecutive men aged ≥18 years with histologically confirmed International Society of Urological Pathology (ISUP) grade 1-5 [15] prostate cancer and with clinically staged T1-T3aN0M0 disease receiving 78 Gy of prostate IMRT. The exclusion criteria included previous pelvic surgery or RT, and a history of Crohn's disease or inflammatory bowel disease.
HS Implant Procedure
Under general anaesthesia and with TRUS guidance, all patients underwent transperineal insertion of three intraprostatic gold seed markers [7] followed by injection of 8-10 mL HS into the anterior perirectal space between Denonvilliers' fascia and the anterior rectal wall (Fig. 1 ).
The HS was implanted by a single radiation oncologist specialised in prostate brachytherapy working in unison with a team of urologists. As there is no simulation available to help with training, important technical expertise of the implantation procedure was disseminated to the urologists by the radiation oncologist, to ensure a high quality insertion of the HS [16] .
Treatment Planning
Pelvic CT for IMRT/VMAT treatment planning was carried out within 5 days after HS injection. All patients were scanned in the supine position with a full bladder and an empty rectum as per our departmental protocol. The treatment plans were created on the Pinnacle v. 9.8 (Philips Radiation Oncology Systems, Fitchburg, WI, USA) treatment planning system (TPS). Clinical target volumes (CTV) comprised of prostate and seminal vesicle and were defined in concordance with the Radiation Oncology Genito-Urinary Group (FROGG) Consensus Guidelines [17] . The CTV to planning target volume (PTV) expansion was 7 mm in all directions except posteriorly, where it was 5 mm. Rectal dose constraint objectives for the volume of rectum receiving 78 Gy (rV 78 ), 75 Gy (rV 75 ), 70 Gy (rV 70 ), 60 Gy (rV 60 ) and 50 Gy (rV 50 ) were 5%, 15%, 20%, 35%, and 50%, respectively. The radiation dose was 78 Gy in 2 Gy daily over 39 fractions.
The rectum was contoured as a whole solid structure beginning at 1.0 cm above the most superior level of the PTV to the anorectal junction. The HS was identified and quantified by manipulating the window values within the Pinnacle TPS. As our patient cohort did not have planning MRI to aid with visualisation of the HS, in the event of any doubt in identifying the HS it was contoured as rectum. The degree of separation achieved between the anterior rectal wall and the posterior edge of the prostate was quantified at the apex, mid-gland, and base. The rV 78 , rV 75 , rV 70 , rV 60 and rV 50 were assessed for correlation between dosimetric endpoints and any GI toxicity.
Data Collection and Follow-up Protocol
Patients were assessed at baseline, weekly during treatment, and at 3-, 6-, and 12-month follow-up visits and then 
Results
Patient Demographics
The 76 patients identified for the study were followed-up over a 2-year period, with only one patient reported lost to followup after completing his course of RT. Our population included men with a median (interquartile range Table 1 .
Rectal Spacing Outcomes
Based on the CT planning data, measured perirectal spacing dimensions resulting from HS injection are shown in Table 2 . The average achievable spacing was very similar across the entire cohort irrespective of prostate size. Table 3 shows mean achievable rectal dose constraints for our patient cohort with relatively low rectal dose volume in the high-dose region of rV 70 and rV 78 (Fig. 2) . Most importantly, these improvements were also observed in the larger prostates, as seen in Fig. 3 .
Dosimetric Outcomes
Toxicity Outcomes
None of the patients reported any rectal bleeding. There were no reports of any adverse events including rectal perforation, or infection after HS injection. In all, 16 patients (21%) developed acute Grade 1 GI toxicity, with all symptoms resolved within 3 months after completion of treatment ( Table 4) . One patient developed a late Grade 1 rectal haemorrhage at 9 months after treatment; however, this was due to rectal haemorrhoids. One patient developed late Grade 1 proctitis at 8 months after treatment. No patients developed late GI toxicity of Grade ≥2. Figure 4 is a breakdown of the incidence of acute radiationinduced GI toxicity at various time-points throughout the 8 week course of RT. As expected the incidence was greatest at the conclusion of treatment with all symptoms resolved at 3 months after RT.
In all, 63 patients (83%) developed acute Grade 1 GU toxicity. These symptoms persisted in 18 (24%) patients 3 months after completion of treatment. Two (3%) patients developed a urinary stricture requiring intermittent selfcatheterisation (Table 4) .
Discussion
Progress in RT techniques in recent years has allowed dose escalation with better PTV coverage, significantly improving treatment outcomes with reduced treatment-associated GI toxicities. Our present study demonstrated that HS was well tolerated with no adverse effects associated with the HS, nor any rectal complications reported in our patient cohort.
In lieu of not having a control group and comparing our HS cohort with our current institution's non-HS patients, the patients receiving the HS implant had rectal dose endpoints that are much lower, particularly in the high-dose region rV 78 : 0.4% vs 4.5%; rV 75 : 3.6% vs 9.5%; rV 70 : 7.8% vs 12.5%; rV 60 : 14.4% vs 19% and rV 50 : 27.3% vs 28.5%. This indicates that the application of HS considerably decreased the amount of the anterior rectal volume being treated, with the mean rV 70 dropping from 12.5% to 7.8% for HS patients. Our present results are in accordance with other published studies [12, 14, 18, 19] and this has further validated our findings. Due to a broad range in prostate size, we also investigated the clinical benefits of HS in larger prostates. Our present study confirmed that rectal dosimetry parameters (Fig. 3) were consistent across the cohort, demonstrating that it is possible to achieve a noticeable reduction in rV 70 irrespective of prostate size. We recognise that our rV 70 and rV 75 are marginally higher (Table 5) [3, 18] than other studies; however, we attribute this finding to our contouring method. In contrast to some studies [3, 14] , where the rectum was contoured from the recto-sigmoid junction to the level of ischial tuberosity, our rectum was contoured from 1.0 cm above the PTV's upper level to the ano-rectal junction. This resulted in a smaller total rectal volume, which in turn resulted in a higher relative rectal dosimetric parameter.
The relatively large reduction in the high-dose regions was the logical explanation for our decreased patient reported GI toxicities. In particular, only 16 patients (20%) had acute Grade 1 GI toxicities, which resolved completely (97%) at 3 months after treatment. The remaining two patients developed either late Grade 1 rectal haemorrhage (one patient) or proctitis (one) at 8 months after treatment. No patients had acute or late Grade ≥2 GI toxicities. Uhl et al. [20] reported similar low Grade 1 GI toxicities at 12 months and no reported Grade ≥2 GI toxicities, whilst slightly higher acute and late GI toxicity rates were noted by Uhl et al. [21] and Whalley et al. [12] .
Our present work builds upon published studies examining the use of HS in our region [12] [13] [14] [22] [23] [24] . In particular, our present findings are comparable to three studies [12] [13] [14] that have reported on rectal dose endpoints and toxicities (late Grade 1), and found them to be significantly lower across all patient groups, with the greatest difference observed in the higher rectal dose (rV 65-82 ) range. More recently, a study by Mariados et al. [18] , examined 222 patients who were randomised to those with HS (n = 149) or without HS (n = 73), whilst undergoing IMRT to a dose of 79.2 Gy in 44 fractions. The authors reported similar results to our present study, with no significant adverse events related to HS injection and no differences in the rates of acute rectal toxicity between the HS and control groups. Another study by Pinkawa et al. [25] , reported on 167 consecutive patients treated either with HS (n = 110) or without HS (n = 66), whilst undergoing prostate RT up to a maximum dose of 80 Gy. These authors also reported similar findings to our present study, in that the HS injection was found to result in favourable rectal dosimetry with minimal acute rectal toxicity during and shortly after RT.
There are a few key strengths to our present study. Firstly, our present study utilised prospective data collection from a Prostate Size <50 cc Prostate Size >50 cc Prostate Size >100 cc large cohort of patients attending a specialist radiation oncology centre in Melbourne, Australia. Secondly, we followed the directives established by the recent consensus statement on the indication and application of HS for prostate RT [26] . Thirdly, we reported minimal acute adverse events during the HS implantation procedure and throughout the 12-month follow-up period. Fourthly, with a single radiation oncologist being involved in the present study, we were quite confident of the level of consistency of the HS injection technique, degree of contouring, and grading of toxicities. Finally, we did not have any restrictions placed on prostate size (i.e. <80 mL) compared to other published data [3, 17, 19, 21] , which allowed analysis of the effectiveness of the HS in its ability to increase the perirectal space, irrespective of prostate volume.
The present study has some limitations, which were not unique to our setting and acknowledged in other published studies that also undertook a single institution research activity using cohort or case-series research designs and small sample sizes. Secondly, we may have missed late Grade 2 GI toxicities, given that toxicities are at risk of occurring 17 months (median) after treatment [12] . Thirdly, patients did not undergo pre-and post-imaging with CT, MRI or both to measure prostate rectum spacing and to define the volume of HS inserted. Lastly, we did not record patientcentred outcomes, such as health-related or disease-specific quality of life.
In conclusion, although our present study was limited in its scope, the study provides clinicians with local data about the application and benefits of HS on reducing GI toxicities during prostate cancer RT. However, if further regionallybased research is going to be conducted, studies must consider using multiple radiation oncology centres and stronger study designs that collect patient-focused clinical and non-clinical outcome measures, dosimetric regimens, longterm safety and effectiveness data that includes not only toxicity but also health-related and disease-specific quality-oflife measures.
